BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $323.17M a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, down 215.7 pp from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 5.52M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the 7th highest of 8, against a peer median of -44.4%.
- Other non-current liabilities amounts to 0.0% of total assets for BBOT, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $351.4M USD | +2955.6% | +44.6% | 115.2% | |
| Mar 2026 | $132.13M USD | +3.9% | +9.9% | 52.1% | |
SEPNSepterna, Inc. | Sep 2026 | $67.13M USD | -44.4% | +12.3% | 10.8% |
| Aug 2026 | $23.38M USD | — | — | 2.0% | |
| Mar 2026 | CHF 1.65M CHF | +27.1% | +144.9% | 0.7% | |
| Sep 2026 | $826K USD | -99.2% | +110.0% | 0.4% | |
| Jun 2026 | $152K USD | -99.8% | — | 0.0% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $0 USD | -100.0% | — | 0.0% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | -3.2% | 0.0% | |
| Peer median (excluding BBOT) | — | -44.4% | +28.5% | 0.7% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.